Mutations upstream of fabI in triclosan resistant Staphylococcus aureus strains are associated with elevated fabI gene expression

BACKGROUND: The enoyl-acyl carrier protein (ACP) reductase enzyme (FabI) is the target for a series of antimicrobial agents including novel compounds in clinical trial and the biocide triclosan. Mutations in fabI and heterodiploidy for fabI have been shown to confer resistance in S. aureus strains i...

Descripción completa

Detalles Bibliográficos
Autores principales: Grandgirard, Denis, Furi, Leonardo, Ciusa, Maria Laura, Baldassarri, Lucilla, Knight, Daniel R, Morrissey, Ian, Largiadèr, Carlo R, Leib, Stephen L, Oggioni, Marco R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415318/
https://www.ncbi.nlm.nih.gov/pubmed/25924916
http://dx.doi.org/10.1186/s12864-015-1544-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415318/
https://www.ncbi.nlm.nih.gov/pubmed/25924916
http://dx.doi.org/10.1186/s12864-015-1544-y

Ejemplares similares